Contents

Current Pharmaceutical Design, Volume 15 - Number 5

Editorial [Hot Topic:Are the Pleiotropic Effects of Drugs Used for the Prevention of Cardiovascular Disease Clinically Relevant?(Executive Editors: M. Elisaf and E.N. Liberopoulos)]

, 15(5): 463 - 466

Moses Elisaf and Evangelos N. Liberopoulos


DOI: 10.2174/138161209787315710




Statins and Cardiovascular Diseases: From Cholesterol Lowering to Pleiotropy

, 15(5): 467 - 478

Qian Zhou and James K. Liao


DOI: 10.2174/138161209787315684




Pleiotropic Effects of Statins - Clinical Evidence

, 15(5): 479 - 489

Vasilios G. Athyros, Anna I. Kakafika, Konstantinos Tziomalos, Asterios Karagiannis and Dimitri P. Mikhailidis


DOI: 10.2174/138161209787315729




Lipid-Lowering Drugs Acting at the Level of the Gastrointestinal Tract

, 15(5): 490 - 516

T. D. Filippatos and D. P. Mikhailidis


DOI: 10.2174/138161209787315738




Pleiotropic Effects of Fenofibrate

, 15(5): 517 - 528

V. Tsimihodimos, E. Liberopoulos and M. Elisaf


DOI: 10.2174/138161209787315675




Effects of Thiazolidinediones Beyond Glycaemic Control

, 15(5): 529 - 536

Rigas G. Kalaitzidis, Pantelis A. Sarafidis and George L. Bakris


DOI: 10.2174/138161209787315693




Fibrates and Microvascular Complications in Diabetes - Insight from the FIELD Study

, 15(5): 537 - 552

J. C. Ansquer, C. Foucher, P. Aubonnet and K. Le Malicot


DOI: 10.2174/138161209787315701




Pleiotropic Effects of Rimonabant: Clinical Implications

, 15(5): 553 - 570

Jean-Pierre Despres


DOI: 10.2174/138161209787315666




Pleiotropic Effects of Drugs Inhibiting the Renin-Angiotensin-Aldosterone System

, 15(5): 571 - 584

P. Jankowski, M. E. Safar and A. Benetos


DOI: 10.2174/138161209787315747




Webmaster Contact: info@benthamscience.org
Copyright © 2018 Bentham Science